Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 101.59M P/E - EPS this Y 3.00% Ern Qtrly Grth -
Income -50.92M Forward P/E -1.83 EPS next Y -7.30% 50D Avg Chg 15.00%
Sales 82M PEG - EPS past 5Y - 200D Avg Chg -2.00%
Dividend N/A Price/Book 0.53 EPS next 5Y - 52W High Chg -65.00%
Recommedations 3.00 Quick Ratio 8.04 Shares Outstanding 52.64M 52W Low Chg 226.00%
Insider Own 15.99% ROA -14.04% Shares Float 29.81M Beta 0.75
Inst Own 85.33% ROE -25.03% Shares Shorted/Prior 2.02M/3.18M Price 1.88
Gross Margin 33.17% Profit Margin -62.10% Avg. Volume 3,466,835 Target Price 2.00
Oper. Margin -63.71% Earnings Date Aug 2 Volume 11,600,631 Change 0.00%
About Jounce Therapeutics, Inc.

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

JNCE Chatroom

User Image BioRich Posted - 1 day ago

$MRKR have loved this one through thick and thin. Miss teaming them with their buddy $JNCE (since bought out). That's how old school I am on this one. Time to accumulate before movement. This will creep up over time. Solid buy and hold as we eye the finish line. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too...that's how we find hidden gems and make money. Let's make some money! Cheers!

User Image KingNeptune Posted - 10/28/24

$GERN beautiful. Different sectors but always think $GERN and $CRMD track each other in their stage of clinical-to-production. Similar to how I saw $MRKR and $JNCE track each other in the past.

User Image NVDAMillionaire Posted - 3 months ago

$JNCE Jounce Therapeutics, Inc. (NASDAQ:JNCE): Transforming Cancer Treatment Through Innovative Immunotherapies http://beyondspx.com/2024/08/05/jounce-therapeutics-inc-nasdaqjnce-transforming-cancer-treatment-through-innovative-immunotherapies/

User Image BioRich Posted - 04/29/24

@TB_Goat my complete bad on this one. That might be why it's been red all of this time. For those that don't know, $JNCE was acquired by Concentra last year (although still showing up on stocktwits as stand alone stock) TB, great catch!

User Image BioRich Posted - 04/26/24

$MRKR ready for a breakout next week. Hopefully pulls $JNCE with it. $VTGN $TERN $CRMD due for a nice week also.

User Image BioRich Posted - 7 months ago

$MRKR nice movement. This should continue to move. Now we just need $JNCE to start getting these kind of gains.

User Image BioRich Posted - 03/28/24

$MRKR $JNCE and $CANF let's end the week strong

User Image BioRich Posted - 03/26/24

$PIRS is there any life with this one anymore? Sold for profit a few years back for around 3$ which is looking pretty good right now. Should have done the same with $JNCE and $MRKR although I think they still have legs as their trial results come in. The Jim Allison science is incredible

User Image vrstock23 Posted - 11 months ago

$NBSE algos are your good friend to get this stock at cheap price. They bring down price for all stocks when there is lack of volume, they don't see if there is SA in progress or how much cash business has. $jnce was brought down below $1 and was finally closed at over $1.8 with offer from Tang capital. $frtx was brought below .6 and company decided to distribute cash with range of 0.9 to 1.1+ so stock just shoot to 50% + when news got published. Here also it looks very safe to me given cash burn is very minimal in last quarter. So only small risk is if management turns rough and give away cash to company it merges with cheap. But that would be very difficult to defend and they will be sued, so I think outcome will be like jnce or frtx. Remember they said in September giving $1 dividend is not in best interest of shareholders and they are working to benefit most to SH

User Image Geddymd72 Posted - 11/24/23

$JNCE I seem to own 25 shares of JNCE^ which is untradable. I assume this is the CVR nontradable contigent Concentra (CVR)?

User Image Stockholm111 Posted - 1 year ago

@John62 Email Kevin Tang and ask him take over... He saved investors when $JNCE management was about to screw retail over

User Image fin_researcher Posted - 10/26/23

#JounceTherapeutics, Inc. and #RedxPharma announced an all-share merger. $JNCE shareholders will own approximately 37% in the new Co. #Investors suspect that the pricing terms of the $JNCE & $REDX M&A deal are #unfair. https://11thestate.com/cases/jnce-redx-mna-investors-case

User Image ikkydiphoenix Posted - 1 year ago

As always Tang and Concentra like to play cheap eh. The point is that if $RAIN board is smart they will rise the price more than $JNCE and won't make the same mistake of $AVIR that has now lost 50%.. The biotech market is dead, interest rates are skyhigh, inflations is huge and there are two big wars going on in the world so refuse would be a move that only id10ts like Avir would make.

User Image LabPsycho Posted - 1 year ago

$KRON At this point, our best hope is for the upcoming clinical results to be an utter failure, and the company immediately ceases operation and liquidates / plans return cash to shareholders / get bought out above cash value. Past year examples are $JNCE $MGTA both up 200-300% from their bottoms. We'd be looking at $3.60-$4.00/share.

User Image ChristmasYime Posted - 1 year ago

@theonlyky nothing I’ve heard of, but not impossible. Keep an eye on SEC filings for +10% equity stock purchases, that’s what happened to $JNCE before buyout

User Image BioRich Posted - 07/26/23

@Justinwoj3 honestly, I haven't calculated $MRKR but have a nice position with them. Science is world renowned so I see them and $JNCE going through the roof (from a science perspective...reviewing the financials) Both are winners. First glance, I think $MRKR catches resistance around 12.80$

User Image BioRich Posted - 07/26/23

$ONON it night take 3 years but this will hit 160$/share. Watching $SRPT to push 108$ by EOM and 121$ by EOA(ugust). Good time to get into $VTGN. $MRKR in a heater...should be followed by $JNCE

User Image WallStArb Posted - 1 year ago

@cayman777 @bullwink @User123321 worst case with most risk is a combo with an unknown private bio - where they are used as a shell - too much unknown and subjective valuation. Best would be a larger bio like $NVS to buy for some premium over tangible book (net cash). Quick and dirty is a deal like $JNCE where it was 85% of net cash + CVR

User Image ktrader1991 Posted - 1 year ago

$JNCE so we got another .021 lease termination per share. Nice

User Image perchedcats Posted - 1 year ago

$TECX tang capital making moves - they bought out jounce $JNCE not long ago, and recebtly made an offer for $AVIR

User Image Stockamateur Posted - 1 year ago

$JNCE why is this stock untradeable?

User Image quickaspeter Posted - 1 year ago

$JNCE $RAIN

User Image Smp92 Posted - 1 year ago

$JNCE $RAIN yup! Was a great play!

User Image nightstocker15 Posted - 1 year ago

$RAIN load up!! remember what Tang did recently at $JNCE he loaded up on shares then offered to buy out the rest at a nice premium! https://www.biopharmadive.com/news/jounce-rival-bid-tang-concentra-redx-merger/645090/

User Image MarketBeat Posted - 1 year ago

Jounce Therapeutics initiated by StockNews.com at hold. www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/ $JNCE

User Image BioRich Posted - 05/31/23

$MRKR like i said if you have $JNCE you need $MRKR

User Image Stockholm111 Posted - 05/26/23

$JNCE Looks like Tang's new remodeled company formerly known a Jounce Therapeutics is now Concentra Biosciences: https://www.concentrabiosciences.com/

User Image Stockholm111 Posted - 05/26/23

$IMMP This is a long shot but if anyone knows about Tang Capital, they know that this guy buys out undervalued biotech plays in large large chunks (He single handedly bought out $JNCE ). I wonder if he's looking at IMMP ? https://www.buzzfile.com/business/Tang-Capital-Management,-LLC-858-200-3830

User Image MarketBeat Posted - 05/24/23

Jounce Therapeutics initiated by StockNews.com at hold. www.marketbeat.com/stocks/NASDAQ/JNCE/price-target/ $JNCE

Analyst Ratings
SMBC Nikko Neutral Feb 24, 23
Raymond James Market Perform Feb 23, 23
Piper Sandler Overweight Jan 3, 23
Raymond James Outperform Nov 11, 22
Raymond James Strong Buy Aug 31, 22
HC Wainwright & Co. Buy Aug 5, 22
Piper Sandler Overweight May 23, 22
Baird Neutral May 11, 22
Raymond James Strong Buy May 6, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
TANG KEVIN C 10% Owner 10% Owner Mar 13 Buy 1.01 85,987 86,847 5,300,087 03/14/23
Trehu Elizabeth Chief Medical Office.. Chief Medical Officer Jan 09 Sell 1.11 9,285 10,306 103,417 01/11/23
MURRAY RICHARD /CA/ CEO and President CEO and President Jan 09 Sell 1.11 45,070 50,028 228,007 01/11/23
Drapkin Kimberlee C CFO and Treasurer CFO and Treasurer Jan 09 Sell 1.11 14,096 15,647 66,018 01/11/23
Cole Hugh M Chief Operating Offi.. Chief Operating Officer Jan 09 Sell 1.11 16,634 18,464 110,082 01/11/23
Trehu Elizabeth Chief Medical Office.. Chief Medical Officer Jan 07 Sell 6.98 8,383 58,513 85,202 01/11/22
MURRAY RICHARD /CA/ CEO and President CEO and President Jan 07 Sell 6.98 37,294 260,312 185,577 01/11/22
Drapkin Kimberlee C CFO and Treasurer CFO and Treasurer Jan 07 Sell 6.98 12,817 89,463 52,614 01/11/22
Cole Hugh M Chief Business Offic.. Chief Business Officer Jan 07 Sell 6.98 9,673 67,518 64,216 01/11/22